Source: Annual Congress 2009 - Lung cancer biology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
L. H. Schmidt, A. Kuemmel, S. Biesterfeld, A. Faldum, D. Weiss, S. Koschmieder, C. Mueller-Tidow, C. Mueller-Tidow, R. Wiewrodt (Muenster, Mainz, Erlangen, Germany). Globo h tumor antigen expression is associated with blood group a1 and negative prognosis in NSCLC. Eur Respir J 2009; 34: Suppl. 53, 290

Member's Comments

No comment yet.

Related content which might interest you: Carbonic anhydrase 9 expression (CA9e) profile combined with growth patterns (GPs) in non-small cell lung cancer (NSCLC) identifies a group of patients with an extremely poor prognosis Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology Year: 2005 Expression of Fhit protein in non-small cell lung cancer (NSCLC) and its correlation with Ki-67, a proliferative marker Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002 Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer Source: Eur Respir J 2004; 23: 14-19 Year: 2004 Tumor specific MUC1 expression in operable lung cancer correlates with improved survival Source: Eur Respir J 2005; 26: Suppl. 49, 459s Year: 2005 Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Does expression of betatubulin 3 correlate between primary non small cells lung cancer tumor and metastases? Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 The expression rate of MAGE A1-6 and SSX4 in lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 457s Year: 2005 The expression of Ki-67, a marker of proliferative activity, in resected nonsmall cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 478s Year: 2001 Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)? Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004 Evaluation of promoter hypermethylation in tissue and blood of non-small cell lung cancer patients and association with survival. Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018 HER2/Neu overexpression as independent negative prognostic factor for non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 The prognostic value of altered pRb and p53 protein expression in non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 363s Year: 2003 Importance of clusterin expression at tissue level for the prognosis of non-small cells lung cancer Source: Annual Congress 2009 - Lung cancer biology Year: 2009 Distribution of BCL-2 gene expression and its prognostic value in non-small cell pulmonary cancer Source: Eur Respir J 2002; 20: Suppl. 38, 72s Year: 2002 Nuclear expression of Y-Box binding protein (YB-1) as a negative prognostic marker in non-small cell lung cancer Source: Annual Congress 2003 - Lung cancer biology Year: 2003 Serum carcinoembryonic antigen (CEA) level as a predictive marker for distant metastasis in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 85s Year: 2006 Her/2 neu and p53 expression in patients with non-small cell lung cancer predict shortened survival Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Clinical evaluation of the plasma levels of hTERT and EGFR expression as markers for early detection of non-small cell lung cancer Source: Annual Congress 2009 - Basic science and lung cancer Year: 2009 Carcinoembryonic antigen mRNA analysis detects micrometastatic cells in blood from lung cancer patients Source: Eur Respir J 2003; 22: 418-421 Year: 2003 Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer Source: Eur Respir J 2015; 46: 1762-1772 Year: 2015